{
    "Clinical Trial ID": "NCT01007942",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Everolimus + Vinorelbine + Trastuzumab",
        "  Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)",
        "INTERVENTION 2: ",
        "  Placebo + Vinorelbine + Trastuzumab",
        "  Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.",
        "  HER2+ status defined as IHC 3+ staining or in situ hybridization positive",
        "  Patients with resistance to trastuzumab",
        "  Prior taxane therapy",
        "  Patients with an ECOG performance status of 0 - 2",
        "  Patients with measurable disease as per RECIST criteria",
        "  Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study;",
        "  Patients must meet laboratory criteria defined in the study within 21 days prior to randomization",
        "Exclusion Criteria:",
        "  Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer",
        "  More than three prior chemotherapy lines for advanced disease.",
        "  Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization",
        "  Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus",
        "  Peripheral neuropathy  grade 2 at randomization",
        "  Active cardiac disease",
        "  History of cardiac dysfunction",
        "  Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer",
        "  Known hypersensitivity to any study medication",
        "  Breastfeeding or pregnant"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progressive-free Survival (PFS) Per Investigator Assessment",
        "  PFS was defined as the time from the date of randomization to the date of first radiologically documented tumor progression or death from any cause, whichever occurs first. PFS primary analysis performed when 415 events were reached. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.",
        "  Time frame: Every 6 weeks until disease progression or death which ever occurred first up to about 41 months",
        "Results 1: ",
        "  Arm/Group Title: Everolimus + Vinorelbine + Trastuzumab",
        "  Arm/Group Description: Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)",
        "  Overall Number of Participants Analyzed: 284",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  7.00        (6.74 to 8.18)",
        "Results 2: ",
        "  Arm/Group Title: Placebo + Vinorelbine + Trastuzumab",
        "  Arm/Group Description: Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)",
        "  Overall Number of Participants Analyzed: 285",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  5.78        (5.49 to 6.90)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 122/280 (43.57%)",
        "  Agranulocytosis 0/280 (0.00%)",
        "  Anaemia 10/280 (3.57%)",
        "  Febrile neutropenia 30/280 (10.71%)",
        "  Immune thrombocytopenic purpura 1/280 (0.36%)",
        "  Leukopenia 3/280 (1.07%)",
        "  Neutropenia 12/280 (4.29%)",
        "  Thrombocytopenia 4/280 (1.43%)",
        "  Acute myocardial infarction 1/280 (0.36%)",
        "  Cardiac failure 1/280 (0.36%)",
        "  Cataract 2/280 (0.71%)",
        "Adverse Events 2:",
        "  Total: 58/282 (20.57%)",
        "  Agranulocytosis 1/282 (0.35%)",
        "  Anaemia 2/282 (0.71%)",
        "  Febrile neutropenia 4/282 (1.42%)",
        "  Immune thrombocytopenic purpura 0/282 (0.00%)",
        "  Leukopenia 0/282 (0.00%)",
        "  Neutropenia 3/282 (1.06%)",
        "  Thrombocytopenia 1/282 (0.35%)",
        "  Acute myocardial infarction 0/282 (0.00%)",
        "  Cardiac failure 0/282 (0.00%)",
        "  Cataract 1/282 (0.35%)",
        "  Cataract subcapsular 1/282 (0.35%)"
    ]
}